Portal de Periódicos da CAPES

Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study

2010; Oxford University Press; Volume: 41; Issue: 3 Linguagem: Inglês

10.1093/jjco/hyq194

1465-3621

S. J. Kim, Kihyun Kım, Yashwant Lamture, Sung-Hwa Bae, Deok‐Hwan Yang, J.-J. Lee,

Protein Degradation and Inhibitors

ObjectiveAcyclovir prophylaxis has been considered as mandatory for patients receiving bortezomib because herpes zoster is a common adverse event associated with the use of bortezomib. Although the minimal effective dose of acyclovir for prophylaxis has not yet established, the efficacy of low-dose acyclovir prophylaxis, 400 mg once daily, has been suggested.